Global Peptide Antibiotics Market and Clinical Pipeline Insight 2023

For Report Sample Contact: neeraj@kuickresearch.com

 

Report Weblink: https://www.kuickresearch.com/report-global-peptide-antibiotics-market-and-clinical-pipeline-insight-2023.php

 

Table of Contents

 

1. Peptide Antibiotics – A New Era for Antibiotics

  1.1 Introduction

  1.2 Systemization of Peptide Antibiotics and Drugs

    1.2.1 Non-Ribosomally Synthesized Peptide Antibiotics

    1.2.2 Ribosomal Synthesized Peptide Antibiotics

2. Mechanism and Production of Peptide Antibiotics

  2.1 Approach of Peptide Antibiotics on Bacterial Surface

  2.2 Creational Process of Peptide Antibiotics

3. Identification of Human Antimicrobial Peptides

  3.1 Human Defensins

  3.2 Human Cathelicidins

  3.3 Antimicrobial Neuropeptides

4. Portrayal of Peptide Antibiotics in Cancer Treatment

  4.1 Introduction

  4.2 Mechanism of Antimicrobial Peptides in Cancer Treatment

5. Categorization of Anticancer Peptides

  5.1 Alpha-Helical Anticancer Peptides

  5.2 Beta-Sheet Anticancer Peptides

6. Approved Peptide Antibiotics

  6.1 Bacitracin

  6.2 Viomycin

7. Market Analysis of Peptide Antibiotics

  7.1 Introduction to Antibacterial Drug Market

  7.2 Global Antimicrobial Peptide Market

8. Market Dynamics of Antimicrobial Peptides

  8.1 Favorable Parameters

  8.2 Challenges

9. Future Perspective of Peptide Antibiotics  Market and Drug Development

10. Global Peptide Antibiotics Clinical Pipeline Overview

  10.1 By Country

  10.2 By Indication

  10.3 By Mode of Action

  10.4 By Formulation

  10.5 By Delivery Route

11. Global Peptide Antibiotics Clinical Pipeline by Company, Indication and Phase

  11.1 Research

  11.2 Preclinical

  11.3 Clinical

  11.4 Phase-I

  11.5 Phase-II

  11.6 Phase-III

  11.7 Preregistration

12. Marketed Peptide Antibiotics Clinical and Patent Analysis

  12.1 Telavancin (Arbelic and Vibativ)

  12.2 Dalbavancin (Dalvance and Xydalba)

  12.3 Daptomycin Intravenous (Cubicin)

  12.4 Oritavancin (Nuvocid and ORBACTIV)

  12.5 Teicoplanin (Targocid)

  12.6 Vancomycin (Vancomycin hydrochloride)

13. Competitive Landscape

  13.1 AMP Therapeutics

  13.2 Eli Lilly

  13.3 GlaxoSmithKline

  13.4 Hospira

  13.5 Kasten

  13.6 Madam Therapeutics

  13.7 Novartis

  13.8 Pacgen Life Science Corporation

  13.9 Pfizer

  13.10 Phosphagenics

  13.11 Savara Pharmaceuticals

  13.12 Theravance

  13.13 Vicuron Pharmaceuticals

 

Figure 1-1: Structure of Some Important Peptide Antibiotics

Figure 1-2: Classification and Characterization of Peptide Antibiotics

Figure 2-1: Targets for Antimicrobial Peptides to Inhibit the Bacterial Growth

Figure 2-2: Chemical Structure of Teixobactin

Figure 2-3: Steps for the Solid Phase Synthesis of Teixobactin

Figure 3-1: Typical Processing of Cathelicidin Protein by Protease Enzymes

Figure 3-2: Mechanism of Antimicrobial Peptides in Defense against Pathogens

Figure 4-1: Angiogenesis Inhibition Mechanism of Action

Figure 6-1: Bacitracin – Mechanism of Action

Figure 7-1: Global – Antibacterial Drug Market (US$ Billion), 2016-2023

Figure 7-2: Usage of Therapeutic Peptides and Proteins in Different Disorders (%)

Figure 7-3: Global – Peptide Drug Market (US$ Billion), 2016-2023

Figure 7-4: Therapeutic Peptide Based Drugs over Route of Administration

Figure 7-5: Global – Peptide Antibiotics Clinical Pipeline by Phase (%), 2017 till 2023

Figure 7-6: Global – Peptide Antibiotics Clinical Pipeline by Phase (Number), 2017 till 2023

Figure 8-1: Favorable Parameters which Helps in the Growth of Antimicrobial Peptide

Figure 8-2: Challenges to Antimicrobial Peptide Market Growth

Figure 9-1: Different Possible Treatment Options of Cancer by Using Peptides

Figure 10-1: Global – Peptide Antibiotics Clinical Pipeline by Country (%), 2017 till 2023

Figure 10-2: Global – Peptide Antibiotics Clinical Pipeline by Indication (%), 2017 till 2023

Figure 10-3: Global – Peptide Antibiotics Clinical Pipeline by Mode of Action (%), 2017 till 2023

Figure 10-4: Global – Peptide Antibiotics Clinical Pipeline by Formulation (%), 2017 till 2023

Figure 10-5: Global – Peptide Antibiotics Clinical Pipeline by Delivery Route (%), 2017 till 2023

 

 

Table 3-1: Cell Sources of Human Defensins Antimicrobial Peptides

Table 9-1: Future Human Antimicrobial Peptides and their Proposed Targets